Although the functional interaction between ubiquitinconjugating enzymes (E2s) and ubiquitin ligases (E3s) is essential in ubiquitin (Ub) signalling, the criteria that define an active E2-E3 pair are not well established. The human E2 UBCH7 (also known as UBE2L3) shows broad specificity for HECT-type E3s 1 , but often fails to function with RING E3s in vitro despite forming specific complexes 2-4 . Structural comparisons of inactive UBCH7-RING complexes with active UBCH5-RING complexes reveal no defining differences 3,4 , highlighting a gap in our understanding of Ub transfer. Here we show that, unlike many E2s that transfer Ub with RINGs, UBCH7 lacks intrinsic, E3-independent reactivity with lysine, explaining its preference for HECTs. Despite lacking lysine reactivity, UBCH7 exhibits activity with the RING-inbetween-RING (RBR) family of E3s that includes parkin (also known as PARK2) and human homologue of ariadne (HHARI; also known as ARIH1) 5,6 . Found in all eukaryotes 7 , RBRs regulate processes such as translation 8 and immune signalling 9 . RBRs contain a canonical C3HC4-type RING, followed by two conserved Cys/His-rich Zn 21 -binding domains, in-between-RING (IBR) and RING2 domains, which together define this E3 family 7 . We show that RBRs function like RING/HECT hybrids: they bind E2s via a RING domain, but transfer Ub through an obligate thioesterlinked Ub (denoted Ub), requiring a conserved cysteine residue in RING2. Our results define the functional cadre of E3s for UBCH7, an E2 involved in cell proliferation 10 and immune function 11 , and indicate a novel mechanism for an entire class of E3s.
Although the functional interaction between ubiquitinconjugating enzymes (E2s) and ubiquitin ligases (E3s) is essential in ubiquitin (Ub) signalling, the criteria that define an active E2-E3 pair are not well established. The human E2 UBCH7 (also known as UBE2L3) shows broad specificity for HECT-type E3s 1 , but often fails to function with RING E3s in vitro despite forming specific complexes [2] [3] [4] . Structural comparisons of inactive UBCH7-RING complexes with active UBCH5-RING complexes reveal no defining differences 3, 4 , highlighting a gap in our understanding of Ub transfer. Here we show that, unlike many E2s that transfer Ub with RINGs, UBCH7 lacks intrinsic, E3-independent reactivity with lysine, explaining its preference for HECTs. Despite lacking lysine reactivity, UBCH7 exhibits activity with the RING-inbetween-RING (RBR) family of E3s that includes parkin (also known as PARK2) and human homologue of ariadne (HHARI; also known as ARIH1) 5, 6 . Found in all eukaryotes 7 , RBRs regulate processes such as translation 8 and immune signalling 9 . RBRs contain a canonical C3HC4-type RING, followed by two conserved Cys/His-rich Zn 21 -binding domains, in-between-RING (IBR) and RING2 domains, which together define this E3 family 7 . We show that RBRs function like RING/HECT hybrids: they bind E2s via a RING domain, but transfer Ub through an obligate thioesterlinked Ub (denoted Ub), requiring a conserved cysteine residue in RING2. Our results define the functional cadre of E3s for UBCH7, an E2 involved in cell proliferation 10 and immune function 11 , and indicate a novel mechanism for an entire class of E3s.
RING and U-box E3s facilitate Ub transfer directly from an activated E2,Ub to a lysine on a target protein. Therefore, E2s that function with RINGs must be catalytically competent to form an isopeptide bond between Ub and lysine. Previous characterization of E2 activity demonstrates that some E2s can transfer Ub to free lysine independent of an E3 (ref. 12) , providing a framework to examine E2 function. We compared the intrinsic, E3-independent reactivity of UBCH7,Ub and UBCH5C,Ub with free amino acids that represent Ub acceptors: lysine, serine, threonine 13 , cysteine 14 , or arginine as a control (Fig. 1a ). UBCH5C,Ub reacts completely with either cysteine or lysine, but not other amino acids, indicating the side-chain functional group is the relevant nucleophile. Notably, UBCH7 reacts only with cysteine. Reaction time courses for UBCH7,Ub and UBCH5C,Ub with free lysine show that UBCH5C,Ub is nearly depleted after 15 min, while after 60 min UBCH7,Ub shows no detectable reaction (Fig. 1b ). The lack of reactivity of UBCH7 is lysine-specific and cannot be attributed to UBCH7,Ub being intrinsically more stable, as both E2s react equally rapidly with cysteine ( Supplementary Fig. 2a ). UBE2K and UBC13, E2s known to function with RINGs 15, 16 , both react with cysteine and lysine ( Supplementary  Fig. 2b ), indicating that lysine reactivity is a general feature of RINGactive E2s. The reactivity properties of UBCH7 are conserved, as the Caenorhabditis elegans orthologue Ubc18 (ref. 17) also lacks lysine reactivity ( Supplementary Fig. 3 ).
To determine which residues in E2s are important for lysine reactivity, the active site sequences of lysine-reactive E2s were aligned with that of UBCH7 ( Fig. 2a ). Two residues in UBCH7 are distinctly different: D87 and D117 (in UBCH5C numbering) are proline and histidine, respectively, in UBCH7. To establish whether these residues contribute to lysine reactivity, each was mutated in UBCH5C and lysine reactivity was measured (Fig. 2b ). The effect of substitution at position 87 ranges from no effect for the isosteric mutation D87N to complete loss of lysine reactivity for the charge-swapped D87K mutation. UBCH5C(D87E) and UBCH5C(D87P) have intermediate reactivities. Consistent with D87 having a general role in lysine reactivity, mutation of the analogous residue in UBE2K(D94E) results in decreased lysine reactivity and impaired formation of free poly-Ub chains ( Supplementary Fig. 4a, b ). Substitution of D117 in UBCH5C with a histidine as found in UBCH7 greatly decreases lysine reactivity ( Fig. 2b) . A structurally analogous residue in the SUMO E2 (D127 in UBC9), has been shown to lower the pK a of a lysine approaching the active site 18 . The invariant active-site asparagine residue (N77 in UBCH5C) is recognized for its role in isopeptide catalysis 19 , and its mutation to serine abolishes UBCH5C,Ub lysine reactivity in our assay. Identification of several residues that affect the intrinsic lysine reactivity of E2s indicates that the determinants are probably multifactorial. Accordingly, we failed to convert UBCH7 into a lysine-reactive E2 by mutation ( Supplementary Table) . To assess whether the intrinsic reactivity of an E2 is predictive of its functional E3 interaction, UBCH5C mutants were assayed with RING and HECT-type E3s. Of the D87 mutants, only UBCH5C (D87N) (which has wild-type lysine reactivity) is able to function with the RING E3 BRCA1/BARD1 in an auto-ubiquitination assay; the other substitutions are inactive ( Fig. 2c ). The observed loss of activity results from E2 catalytic defects, as NMR binding experiments confirm that UBCH5C(D87) mutants bind BRCA1 comparably to wild-type UBCH5C ( Supplementary Fig. 5 ). UBCH5C(D117H), which has impaired lysine reactivity, retains some ability to transfer Ub to BRCA1 ( Fig. 2c ). Given its position at the active site, D117 may provide substrate-specific lysine reactivity as a gating residue. As expected, UBCH5C(N77S) is inactive with BRCA1. Previous studies show that mutation of E2 residue N77 abolishes Ub transfer with RING-type ligases MDM2 (ref. 19) , RMA1 (also known as RNF5) (ref. 20) , CNOT4 (CCR4-NOT transcription complex subunit 4) and APC/C (anaphase promoting complex/cyclosome) (ref. 21) but retains activity with HECT-type ligases E6-AP (also known as UBE3A), KIAA10 (also known as UBE3C; ref. 19 ) and NEDD4L (ref. 22 ). This indicates that the catalytic requirements for trans-thiolation differ from those for isopeptide bond synthesis. Accordingly, the ability to form E3,Ub thioesters with the HECT E3 E6-AP is unaffected in all UBCH5C mutants ( Supplementary Fig. 6 ).Taken together, our results indicate that E2 lysine reactivity is a prerequisite for transfer with RING E3s. Furthermore, lysine-unreactive E2s, such as UBCH5C(N77S), can be diagnostic for differentiating between RING-versus HECT-type Ub transfer mechanisms.
Although many E2s possess an intrinsic reactivity for lysine, most do not transfer Ub to protein substrates independent of an E3. To explore the contribution of E3s to E2 reactivity, we examined the intrinsic reactivity of E2,Ub in the presence of RING or HECT E3s. Interaction with BRCA1/BARD1 (RING) or E6-AP (HECT) does not change the intrinsic reactivity of UBCH5C and UBCH7 with free amino acids ( Supplementary Fig. 7a, b ). However, BRCA1/BARD1 enhances UBCH5C,Ub lysine reactivity compared to a reaction containing the E2-binding mutant BRCA1(I26A) 3, 15 (Fig. 2d ). Intriguingly, the lysine reactivity of UBCH5C(D87E), which retains both its ability to bind BRCA1/BARD1 and some intrinsic lysine reactivity, is not enhanced by BRCA1 (Fig. 2d ). These results indicate that RING binding to a lysine-reactive E2,Ub results in a thioester with enhanced reactivity to lysine and residues such as D87 in UBCH5C couple E3 binding and E2 activation. Notably, E6-AP does not enhance UBCH5C,Ub lysine reactivity ( Supplementary Fig. 8b ), highlighting a mechanistic difference between RINGs and HECTs. In matched experiments with UBCH7, neither BRCA1/BARD1 nor E6-AP enhance reactivity towards free cysteine ( Supplementary Fig. 8a, c) .
Besides HECT-type ligases, UBCH7 is reported to function with members of the RING E3 family known as RBRs, which includes parkin and HHARI 5, 6 . This activity runs contrary to our conclusion that UBCH7 lacks lysine reactivity and is consequently restricted to Ub transfer involving trans-thiolation chemistry. Therefore, we examined the Ub ligase mechanism for HHARI and parkin. The minimal ligase (RBR) domains of HHARI R1-IBR-R2 (where R1 and R2 are RING1 and 2, respectively) and parkin R1-IBR-R2 (see Supplementary Fig. 9 for schematic of constructs) show comparable auto-ubiquitination activity with either UBCH7 or UBCH5C (Fig. 3a, b) . In contrast to our results with BRCA1/BARD1, UBCH5C(N77S) exhibits Ub transfer with HHARI R1-IBR-R2 and parkin R1-IBR-R2 (Fig. 3a, b ). As UBCH5C(N77S) activity is restricted to HECT-type ligases, its activity with parkin and HHARI indicates that these ligases do not function via a typical RING-type mechanism.
A hallmark of HECT-type Ub transfer is the formation of an obligate E3,Ub thioester intermediate. Reactions designed to trap a HHARI,Ub conjugate were conducted on ice and quenched with SDS-loading buffer with or without reducing agent (bME) to distinguish reducible thioester-linked Ub from non-reducible isopeptidelinked Ub. A bME-sensitive band corresponding to the molecular 
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weight of HHARI,Ub was detected at 10, 20, and 30 s after addition of pre-charged UBCH7,Ub (Fig. 3c ). We next sought to determine the position of the HHARI active-site cysteine. The N-terminal canonical RING1 of HHARI has been shown to be the principal E2-binding region 23 , although RING2 is also required for ligase activity 5 . Cysteine 357 in RING2 is highly conserved across RBR ligases (Fig. 4a ). C357 is not a Zn 21 -liganding residue, and mutation of C357 does not destabilize the RING2 structure 5 ( Supplementary Fig.  10 ), but does abolish the ability of HHARI to transfer Ub 5 . This indicates that C357 may have a catalytic function. Although HHARI R1-IBR-R2 (C357A) showed no ligase activity in an autoubiquitination assay, HHARI R1-IBR-R2 (C357S) generated a single monoubiquitinated species (Fig. 4b ). An analogous oxyesterlinked Ub product can be generated on E2s for which the activesite cysteines have been mutated to serines 20, 22, 24 . Consistent with its identity as an oxyester (versus isopeptide) bond, the Ub adduct on HHARI R1-IBR-R2 (C357S) is labile to alkaline treatment (Supplementary Fig. 11 ). Formation of an oxyester is unique to C357 as serine substitution of other conserved cysteines (both Zn 21 -and non-Zn 21 -liganding) in RING2 does not stall the E3 at a single-Ub adduct but rather impairs (C375S) or abolishes (C367S, C372S) ligase activity ( Supplementary Fig. 12) . Similarly, the parkin mutant C431S (analogous to HHARI(C357)) eliminates E3 ligase activity (Fig. 4c ). We were unable to trap a parkin R1-IBR-R2 (C431S) Ub adduct under our reaction conditions. However, we note that the parkin mutation C431F has been consistently shown to abolish parkin's ubiquitination of substrates [25] [26] [27] and genetically predisposes for Parkinson's disease 28 . The results presented above are not affected by the presence of a GST domain, as several results were reproduced with non-GST versions of HHARI ( Supplementary Fig. 13 ). HHARI R1-IBR-R2 (C357A) effectively binds E2 as GST pull-downs with purified UBCH7 and constructs of GST-HHARI demonstrate that HHARI R1-IBR-R2 (C357A) interacts with UBCH7 as efficiently as wild-type HHARI R1-IBR-R2 (Fig. 4d) . In contrast, a HHARI-RING1 mutant (I188A 23 , analogous to BRCA1(I26A)) does not interact detectably with UBCH7 in this assay. Furthermore, C357 is surface accessible and reactive, as wild-type HHARI R2 but not HHARI R2 (C357A) is readily derivitized by cysteine-modifying reagents ( Supplementary  Fig. 14) .
In the absence of a bona fide substrate, an in vitro product of HHARIcatalysed Ub transfer is the non-reducible ubiquitination of UBCH7 (Fig. 4b) . Ubiquitination of UBCH7 is E3-dependent, and mutation of HHARI R1-IBR-R2 (C357) to serine or alanine abolishes the formation of this product (Fig. 4b ). Our finding that HHARI R1-IBR-R2 (C357S) forms an oxyester-linked Ub without subsequent transfer of Ub to UBCH7 indicates an ordered mechanism that involves formation of an E3,Ub before modification of UBCH7 (or substrates). Thus, HHARI, unlike other RING E3s, does not facilitate direct transfer from an E2,Ub to a target. We note that the HHARI oxyester-linked Ub conjugate accumulates in low yield compared to the available number of active sites. This is consistent with our failure to observe intrinsic serine reactivity for UBCH7, even at serine concentrations as high as 0.5 M ( Fig. 1a and data not shown) and suggests that the unique chemical environment surrounding a target residue (in this case an enzyme active site) contributes to catalysis-a contribution that is absent in the nucleophile auto-ubiquitination assays with the indicated E2 were visualized on a Coomassie-stained reducing SDS gel. Time is measured as minutes after ATP addition. b, Auto-ubiquitination assay of parkin R1-IBR-R2 with the E2s indicated. Products were visualized by western blotting for the GST tag on parkin. c, UBCH7 was pre-charged with HA-Ub and mixed with HHARI R1-IBR-R2 . Reactions were quenched in SDS buffer under reducing (1bME) and nonreducing conditions (2bME) and visualized by western blotting for the HA epitope on Ub. A bME-sensitive HA-Ub band corresponding to the molecular weight of HHARI R1-IBR-R2 -Ub appears at 10, 20 and 30 s after addition of UBCH7,Ub. Asterisk denotes a cross-reactive band. 
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assay. Our combined results are consistent with HHARI and parkin functioning via a HECT-like mechanism whereby RING1 harbours the E2-binding site and RING2 harbours the active-site cysteine. Our characterization of the reactivity of UBCH7 resulted in two unexpected discoveries. First, whereas E2s known to work with RING-type E3s have E3-independent reactivity towards lysine, the intrinsic reactivity of UBCH7 is restricted to cysteine and, consequently, its Ub transfer activity is restricted to HECT-type ligases. Second, in the process of confirming reports that UBCH7 is active with E3s in the RBR family, we discovered that these RING-containing E3s function like HECTs in that they require an obligate trans-thiolation step during Ub transfer. Both findings have important implications for guiding our understanding of ubiquitination pathways. RING1 of HHARI does not harbour catalytic activity, and neither HHARI R1-IBR nor HHARI R2 enhance lysine reactivity of UBCH5C ( Supplementary Fig. 15 ). Our results underscore the diversity of structures that facilitate thiol-based Ub transfer, enzymes that include bacterial HECT-like E3s that bear no homology to eukaryotic HECT counterparts 29 . Knockdown and overexpression studies indicate that UBCH7 regulates S-phase progression into G2, but neither the E3(s) nor targets responsible have been identified 10 . Our results indicate that the relevant E3(s) will be found among HECT or RBRs. Although it is possible that UBCH7 cooperates with RINGs such as BRCA1 to modify substrate cysteines, we have not observed such species.
Among human E2s, only five residue types are found at the position analogous to D87 of UBCH5C: aspartate, serine, asparagine, glutamate and proline. The tolerance for asparagine and serine at position 87 indicates that the negative charge of D87 may not be critical for its role in catalysis, but instead a hydrogen-bonding function seems likely, possibly interacting with the conjugated Ub. Of human E2s, only UBCH7 and UBCH8 have a proline at position 87. Although we did not test UBCH8 for lysine reactivity, it functions primarily with the HECT-type ligase HERC5 to transfer the Ub-like protein ISG15 to substrates 30 . Like UBCH7, we anticipate UBCH8 activity will be limited to HECT or RBR E3s. Our effort to understand the mechanism of UBCH7mediated Ub transfer highlights the predictive power of elucidating E2 mechanisms to understand the E3s with which they function.
METHODS SUMMARY
Plasmids, protein expression/purification, E3 auto-ubiquitination assays and NMR experiments were performed as described previously 3, 15 . Modifications and details are described in Methods. For intrinsic reactivity assays, E2s were charged with Ub for 20-30 min at 37 uC before addition of cysteine, arginine, lysine, serine, threonine or buffer (final concentration 50 mM, pH 7.0). After 15-20 min, reactions were quenched in non-reducing loading-buffer and visualized by Coomassie-stained SDS-PAGE. Reactivity time courses with lysine and cysteine were performed similarly with samples quenched at the indicated times.
